Index
Note: Page numbers followed by “f” and “t” refer to figures and tables, respectively.
A
Acellular dermal matrix (ADM) topography,
81–82,
82
Alternating magnetic fields (AMFs),
161,
161
5-Aminolevulinic acid (5-ALA),
154,
155
Animal models, in cancer nanotechnology,
45
Antisense oligonucleotides (AONs),
161,
163
Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL),
161–163
Arginine–glycine–aspartic acid (RGD) peptide,
50,
160
Atomic force microscopy
curcumin-loaded SF nanoparticles, characterization of,
24B
BALB/cBYJNarl mice, in cancer nanotechnology,
49
β-cyclodextrin (β-CD),
124
Biodistribution of nanoparticles,
46–47,
47
Bombyx mori silk fibroin (SF)-based scaffolds,
87
materials and methods,
89–90
conformation analysis using FTIR,
90mechanical properties measurement using uniaxial tensile testing,
90porosity measurement,
89–90SF solution particle size measurement using DLS,
893D architecture characterization using SEM,
89
changes in scaffold structure, FTIR peak analysis of,
97,
98f,
99tfilter size effect on scaffold properties,
93–94,
93t,
94fPBS concentration effect on scaffold properties,
94–97,
96t,
97fpH effect on scaffold properties,
94,
95f,
95tSF concentration effect on particle size in solution,
90,
91tSF concentration effect on scaffold properties,
90–93,
92f,
92f
therapy
nanotechnologies for,
171
Breast-derived fibroblasts (BDFs),
81
C
Cadmium selenide (CdSe),
50
Cancer hyperthermia, noninvasive radiofrequency
biological RF activity of AuNPs in vitro/in vivo,
13–15,
14f,
15fRF interactions with AuNPs,
7–10,
8f,
9f
Capsular contraction,
72,
73t
Carboplatin-Fe@C-loaded chitosan nanoparticles,
61,
61
Carrier-mediated transport (CMT),
176–177
Cationic albumin-conjugated polyethylene glycol (PEG)-coated nanoparticles (CBSA-NP-ACL),
144–145
Cellular ingrowth, surface texturing and,
79–80
Celsius421 GmbH,
blood–brain barrier, crossing,
142–145multidrug resistance, overcoming,
148–150selectively targeting cancer cells,
145–147Chitosan surface-modified poly(lactide-co-glycolides) (PLGA/CS) nanoparticles,
149–150
Classical electromagnetic theory,
11–12
Computed tomography (CT),
48
Confocal laser scanning microscope,
49–50
Cowpea mosaic virus (CPMV),
63
-activated apoptotic pathways, protein array analysis of,
29–38,
30f,
31f,
31t,
32f,
33f,
34f,
35f,
36f,
37f,
38f,
39f,
40f,
41fchemical structure of,
20f-loaded SF nanoparticles
biological evaluation of,
25–26,
25,
25–27,
26t,
29–38,
30f,
31f,
31t,
32f,
33f,
34f,
35f,
36f,
37f,
38f,
39f,
40f,
41fcharacterization of,
23–24,
23–24,
24,
24,
24,
24,
27,
27,
27f,
28,
28f
release profile from SF nanoparticles,
24solution, preparation of,
22D
1,2-Dihexadecanoyl-sn-glycero-3-phosphoethanolamine (DPPE),
124
Doxorubicin (DOX),
45–46,
54,
55,
58,
58,
59,
111–112,
112,
124,
174
DOX-SPIO nanoparticles,
49
Drug loading efficiency,
24,
28
Dynamic light scattering (DLS),
10
curcumin-loaded SF nanoparticles, characterization of,
24SF solution particle size measurement using,
89E
Electrophoretic model,
12–13
Enhanced permeability and retention (EPR) effect,
49–50,
109,
145,
180
F
Ferumoxtran (Combidex),
120
Folate receptor-targeted liposomal oridonin (F-L-ORI),
55
Fourier transform infrared (FTIR) spectroscopy, conformation analysis using,
90
G
for hyperthermia,
GILM2 metastatic breast cancer cells, curcumin efficacy against,
25,
29,
29f
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
55
Gold nanoparticles (AUNPs),
183
applications in photothermal therapy,
60for noninvasive radiofrequency cancer hyperthermia, ,
5f,
6f
biological RF activity of AuNPs in vitro/in vivo,
13–15,
14f,
15fRF interactions with AuNPs,
7–10,
8f,
9f
Graphene oxide-superparamagnetic iron oxide hybrid nanocomposite (GO-IONP-PEG),
112–114
Graphene quantum dots (GQDs),
53
Gum Arabic–stabilized gold nanocrystals (GA-AuNPs),
52–53
H
High-intensity focused ultrasound (HIFU),
61
Hydrophilic carbon clusters (HCCs),
58
1-Hydroxyethylidene-1,1-bisphosphonic acid–coated SPIO nanoparticles,
152
I
ILK signaling pathway
curcumin-activated, protein array analysis of,
34,
37fImage-guided radiotherapy,
51
Implant surface texturing,
76t
and cellular ingrowth,
79–80cellular response to,
74–75history and development of,
75–76utility of nanotechnology,
80–81Insulin receptor signaling pathway
curcumin-activated, protein array analysis of,
32,
36fIntegrin antagonist (IA),
62,
62
Intraoperative delineation of tumors,
154–155
J
K
Karnofsky performance status (KPS),
172
KB tumors, nude mice with,
52
KRAS (Kirsten rat sarcoma) allele,
59,
60
L
Laser-activated nano-thermolysis as a cell-elimination technology (LANTCET),
60,
60–61
Lipopolysaccharide (LPS),
63
Liposomal belotecan,
45–46
Liposomal delivery systems,
54
Liposome-gold nanoparticle (LiposAU NP),
60
M
Magnetic fluid hyperthermia,
182–183
MDA-MB-231 breast cancer tumor cells,
46
Meso-2,3-dimercaptosuccinic acid (DMSA),
124
Metastatic breast cancer,
19
GILM2 cells, curcumin efficacy against,
25,
29,
29f
O6-Methylguanine methyltransferase (MGMT),
149–150
Monoclonal antibodies,
176
Multidrug resistance (MDR),
173–174
Multi-walled carbon nanotubes (MWCNTs),
163
N
Nanoliposomal irinotecan (nal-IRI),
54,
54,
54–55
Nanoliposomal topotecan (nLs-TPT),
57–58
as diagnostic imaging tools,
48–52structural and functional properties,
143tas theranostic tool,
52–53use in pharmacokinetics,
45–48
Nanoscale ceramide liposomes,
55
Nanotechnology
for brain tumor therapy,
171in neurosurgical oncology,
139utility in implant surface texturing,
80–81
Near-infrared fluorescent (NIRF) imaging,
50
Neurosurgical oncology, nanotechnology in,
139
neurotoxicity of nanoparticles,
164–165
blood–brain barrier, crossing,
142–145multidrug resistance, overcoming,
148–150selectively targeting cancer cells,
145–147
future directions of,
166
radiation damage to tumors, targeting,
150–152radiation-induced brain damage, repair of,
152–153
intraoperative delineation of tumors,
154–155
Neurotoxicity of nanoparticles,
164–165
Noninvasive radiofrequency cancer hyperthermia, AuNPs for, ,
5f,
6f
biological RF activity of AuNPs in vitro/in vivo,
13–15,
14f,
15fRF-induced AuNPs heating, theoretical frameworks for,
11–13
classical and quantum electromagnetic theory,
11–12electrophoretic model,
12–13
RF interactions with AuNPs,
7–10,
8f,
9fNoninvasive radiofrequency hyperthermia systems, overview of,
3–4
Non-PEGylated nanoparticles,
45–46
O
Octopod magnetite nanoparticles,
121,
122f
P
p70S6K Signaling pathway
curcumin-activated, protein array analysis of,
34–37,
40f
nanoparticles, albumin-bound,
20
PEGylated hydrophilic carbon clusters (PEG-HCCs),
58
Pharmacokinetics, nanoparticles’ use in,
45–48
Phase-shift nanoemulsions (PSNEs),
61
Photodynamic therapy (PDT),
159–160
PI3K/AKT signaling pathway
curcumin-activated, protein array analysis of,
32,
35f,
37–38,
41fPolyacrylic acid (PAA),
121
Poly(β-amino ester)s (PBAEs),
163–164
Polybutylcyanoacrylate (PBCA),
182
Polydimethylsiloxane (PDMS),
81–82,
82
Polyethylene glycol (PEG),
45–46,
58
Polyethylene imine (PEI),
124
Polyglycolide (PLGA),
181
Polyisohexlcyanoacrylate,
54
Poly lactic-
co-glycolic acid (PLGA)-coated magnetic nanospheres,
61–62
Polylactide-
co-glycolide matrix (PLGA-MNPs),
112
Polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles,
58,
59
Porphyrin-based lipoproteins (PLPs),
52,
52
Positron emission tomography (PET),
50
Protein array analysis, of curcumin-activated apoptotic pathways,
29–38,
30f,
31f,
31t,
32f,
33f,
34f,
35f,
36f,
37f,
38f,
39f,
40f,
41f
Protein expression analysis, using protein array,
25–26,
26t
Q
linked to alpha-fetoprotein antibody (QDs-Anti-AFP),
50–51Quantum electromagnetic theory,
11–12
R
Radiation damage to tumors, targeting,
150–152
Radiation-induced brain damage, repair of,
152–153
Radioactive nanoliposomes,
57
Radiochemotherapeutics,
51–52
Recombinant proteins,
176
Reduced GO nanomeshes (rGONMs),
160
Reduced graphene oxide nanoplatelets (rGONPs),
160
Reticuloendothelial system (RES),
52,
54,
109
Rhenium (
188Re)-labeled nanoliposomes,
57
S
Salt loss technique,
77,
78f
Scanning electron microscopy (SEM)
curcumin-loaded SF nanoparticles, characterization of,
23–243D architecture characterization using,
89
Signal photon-emission computed tomography (SPECT),
51–52
Silk fibroin (SF)
chemical structure of,
21fSilk fibroin nanoparticles, cancer therapy using,
19
curcumin-loaded SF nanoparticles, biological evaluation of,
25–27
apoptotic pathways activated by curcumin, protein array analysis of,
29–38,
30f,
31f,
31t,
32f,
33f,
34f,
35f,
36f,
37f,
38f,
39f,
40f,
41fGILM2 metastatic breast cancer cells, curcumin efficacy against,
25,
29,
29fprotein expression analysis using protein array,
25–26,
26t
curcumin-loaded SF nanoparticles, characterization of,
23–24
atomic force microscopy,
24curcumin release profile from SF nanoparticles,
24drug loading efficiency,
24drug loading efficiency and release kinetics,
28dynamic light scattering,
24particle size distribution,
27,
28fscanning electron microscopy,
23–24
curcumin-loaded SF nanoparticles, preparation of,
22–23,
23fmethods
curcumin solution, preparation of,
22SF nanoparticles, preparation of,
22–23SF solution, preparation of,
22,
22f
Sprague Dawley rats, in cancer nanotechnology,
49,
61
Surface-enhanced Raman scattering (SERS),
155,
155
Surface nanoparticles, and infection prevention,
82–83
Surface plasmonic resonance (SPR),
5–6
Surface printing, three-dimensional,
81–82
T
solid lipid nanoparticles (TMZ-SLNs),
144,
144ftHA-LIP-DXR (doxorubicin-loaded targeted hyaluronan liposomes),
54
Thermotron RF-8, ,
Thomsen–Friedenreich (TF) antigen,
51
Three-dimensional surface printing,
81–82
D-Threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP),
56
Thyroid-stimulating hormone (TSH) nanoliposomes,
57
Transforming growth factor-β (TGF-β),
163
U
Ultrasmall superparamagnetic iron oxide (USPIO),
49
Uniaxial tensile testing,
90
Upconversion nanoparticles (UCNPs),
160
V
Vascular endothelial growth factor (VEGF),
46
Vascular endothelial growth factor receptor (VEGFR),
46
Y
YIGSR nanoparticles (YISR-NPs),
47